Drug – bio-affecting and body treating compositions – Lymphokine – Interferon
Reexamination Certificate
2007-07-03
2007-07-03
Saoud, Christine J. (Department: 1647)
Drug, bio-affecting and body treating compositions
Lymphokine
Interferon
C424S085400, C514S012200, C530S350000, C530S351000, C530S395000, C530S397000
Reexamination Certificate
active
10325720
ABSTRACT:
The present invention provides new interferon β conjugates, methods of preparing such conjugates and the use of such conjugates in therapy, in particular for the treatment of multiple sclerosis.
REFERENCES:
patent: 4588585 (1986-05-01), Mark et al.
patent: 4686191 (1987-08-01), Itoh et al.
patent: 4769233 (1988-09-01), Bell et al.
patent: 4904584 (1990-02-01), Shaw
patent: 4914033 (1990-04-01), Bell et al.
patent: 4917888 (1990-04-01), Katre et al.
patent: 4966843 (1990-10-01), McCormick et al.
patent: 5206344 (1993-04-01), Katre et al.
patent: 5218092 (1993-06-01), Sasaki et al.
patent: 5376567 (1994-12-01), McCormick et al.
patent: 5382657 (1995-01-01), Karasiewicz et al.
patent: 5545723 (1996-08-01), Goelz et al.
patent: 5738846 (1998-04-01), Greenwald et al.
patent: 5795779 (1998-08-01), McCormick et al.
patent: 6531122 (2003-03-01), Pedersen et al.
patent: 2003/0170206 (2003-09-01), Rasmussen et al.
patent: 2003/0175240 (2003-09-01), Pedersen et al.
patent: 083 069 (1987-09-01), None
patent: 0 287 075 (1988-10-01), None
patent: 0 370 205 (1990-05-01), None
patent: 041 313 (1990-09-01), None
patent: 229 108 (1990-12-01), None
patent: 260 350 (1992-02-01), None
patent: 0 529 300 (1993-03-01), None
patent: 287 075 (1995-01-01), None
patent: 539 300 (1996-02-01), None
patent: 593 868 (1998-04-01), None
patent: WO 95/25170 (1995-09-01), None
patent: WO 95/27502 (1995-10-01), None
patent: WO 98/35026 (1998-08-01), None
patent: WO 98/48018 (1998-10-01), None
patent: WO 99/03887 (1999-01-01), None
patent: WO 99/55377 (1999-11-01), None
patent: WO 99/55377 (1999-11-01), None
patent: WO 99/67291 (1999-12-01), None
patent: WO 00/23114 (2000-04-01), None
patent: WO 00/23472 (2000-04-01), None
patent: WO 00/26354 (2000-05-01), None
Ngo et al., 1994, The Protein Folding Problem and Tertiary Structure Prediction, pp. 492-495.
Wells, Aditivity of Mutational Effects in Proteins, 1990, Biochemistry, vol. 26, No. 37, pp. 8509-8517.
Derwent Abstract 012152872 for WO 98/48018, a German publication cited in previous IDS Form-1449.
Derwent Abstract 009442954 for EP 539 300, a French publication cited in previous IDS Form-1449.
Fierlbeck et al., “Neutralising interferon β antibodies in melanoma patients treated with recombinant and natural interferon β”Cancer Immunol Immunother(1994) 39:263-268.
Karpusas et al., “The Structure of Human Interferon- β: Implications for activity”CMLS54 (1998) 1203-1216.
Karpusas et al., “The crystal structure of human interferon β at 2.2 A resolution” Proc. Nat. Acad. Sci. USA (1997) 94:11813-11818.
Mayorga et al., “Antibodies to Commercially Available Interferon-Bet Molecules in Mulitpule Sclerosis Patients Treated with Natural Interferon-Beta”Int. Arch. Allery Immunol1999; 118:368-371.
Munschauer et al., “Managing Side Effects of Interferon-Beta in Patients with Relapsing-Remitting Multipule Sclerosis”Clinical Therapeuticsvol. 19, No. 5, 1997 883-893.
Redlich et al., “Antibodies that neutralize human β interferon biologic activity recognizing a linear epitope: Analysis by synthetic peptide mapping”Proc. Natl. Acad. Sci. USAvol. 88, pp. 4040-4044 May 1991.
Rudick et al., “Incidence and significance of neutralizing antibodies to interferon beta-1a in multipule sclerosis”NeurologyMay 1889, 50: 1266-1272.
Runkel et al., Structural and Functional Differences Between Glycosylated and Non-Glycosylated Forms of Human Interferon- β (IFN- β)Pharmaceutical Researchvol. 15, No. 4, 1998, 641-649.
Runkel et al, 1998, Jour. Biol. Chem. Difference in Activity between α and β Type I Interferons Explored by Mutational Analysis 273, No. 14, pp. 8003-8008.
Senda et al., “Refined Crystal Structure of Recombinant Murine Interferon- β at 2.15 A Resolution”J. Mil. Biol.(1995) 253, 187-207.
Stewart et al, DNA Chemical Mutagenesis of Human Interferon- β: Construction, Expression inE. coli, and Biological Activity of Sodium Bisulfite-Induced Mutations vol. 6 No. 2 1987 p. 119-128.
Tanigunchi, et al., “The nucleotide sequence of human fibroblast interferon cDNA”Gene10 (1980) 11-15.
Yong et al., “Interferon beta in the treatment of multiple sclerosis”Neurology1998; 51: 682-689.
Apweiler et al., “On the frequency of protein glycosylation, as deducted from analysis of the SWISS-PROT database,”Biochim. Biophys. Acta1473:4-8 (1999).
O'Connell et al., “The Influence of Flanking Sequences on O-Glycosylation,”Biochemical and Biophysical Research Communications:180(2):1024-1030 (1991).
Andersen Kim Vilbour
Bornaes Claus
Pedersen Anders Hjelholt
Rasmussen Poul Baad
Maxygen Inc.
Petithory Joanne R.
Powers Margaret A.
Saoud Christine J.
Seharaseyon Jegatheesan
LandOfFree
Interferon-β variants and conjugates does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Interferon-β variants and conjugates, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Interferon-β variants and conjugates will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3779789